Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

20 May 2003

A prospective open study of extended lamivudine treatment in children with chronic hepatitis B unresponsive to previous interferon alpha therapy

D. Lebensztejn, E. Skiba, O. Kovalchuk, M. Kaczmarski, L. Chyczewski

Med Sci Monit 2003; 9(2): 11-0 :: ID: 15252

Abstract

Background:Lamivudine is an inhibitor of HBV replication which is efficient and well tolerated in adults with chronic hepatitis B.Data regarding the effect of extended Lamivudine treatment in children who failed to respond to previous IFN a therapy are scarce.Therefore,the effects of Lamivudine treatment on ALT activity,HBV DNA,HBeAg and HBsAg seroconversion as well as the occurence of YMDD variant and adverse effects were determined.Material/Methods:The observation was carried out on 41 children,aged 4 –17 years,with biopsy-proven chronic hepatitis B (HBeAg+,HBV DNA+,wild-type virus+),who were nonresponders to previous IFN a therapy.Lamivudine in the dose of 3 –4 mg/kg/day up to 100mg/day was given for 18 months.Results:40 children completed 12 months and 25 of them –18 months of therapy;one boy was excluded from this study due to severe thrombocytopenia.After 6 months of Lamivudine therapy 62.2%of children cleared HBV DNA,59.3% normalized AlAT activity and only 1 child (2.5%)lost HBeAg. After a year of therapy 25%of children cleared HBV DNA, 81.5% normalized ALT activity and 10%lost HBeAg.At the end of 18 months therapy in the group of 25 children 40%of them cleared HBV DNA,20%seroconverted to antiHBe and 76.5%normalized ALT activity.No adverse effects were noted, except thrombocytopenia.YMDD variant was present in 20% of children after one year of therapy and in 32%–6 months later. Conclusions:The 18-month-treatment with Lamivudine in children with chronic hepatitis B who did not respond to IFN a normalized ALT activity in most children and caused seroconversion to antiHBe in 20%.However it was associated with a high risk for developing YMDD mutation.

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

26 Feb 2024 : Clinical Research  

Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...

Med Sci Monit In Press; DOI: 10.12659/MSM.942509  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750